Lixte Change In Working Capital from 2010 to 2024

LIXTW Stock  USD 0.03  0.0001  0.36%   
Lixte Biotechnology Change In Working Capital yearly trend continues to be fairly stable with very little volatility. Change In Working Capital is likely to outpace its year average in 2024. Change In Working Capital is the difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities. View All Fundamentals
 
Change In Working Capital  
First Reported
2006-03-31
Previous Quarter
61.2 K
Current Value
-140.4 K
Quarterly Volatility
106.7 K
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lixte Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lixte Biotechnology's main balance sheet or income statement drivers, such as Interest Expense of 17 K, Other Operating Expenses of 2.7 M or EBITDA of 3.4 K, as well as many indicators such as Price To Sales Ratio of 9.35, Dividend Yield of 0.0011 or PTB Ratio of 1.18. Lixte financial statements analysis is a perfect complement when working with Lixte Biotechnology Valuation or Volatility modules.
  
Check out the analysis of Lixte Biotechnology Correlation against competitors.

Latest Lixte Biotechnology's Change In Working Capital Growth Pattern

Below is the plot of the Change In Working Capital of Lixte Biotechnology Holdings over the last few years. It is the difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities. Lixte Biotechnology's Change In Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lixte Biotechnology's overall financial position and show how it may be relating to other accounts over time.
Change In Working Capital10 Years Trend
Very volatile
   Change In Working Capital   
       Timeline  

Lixte Change In Working Capital Regression Statistics

Arithmetic Mean19,065
Coefficient Of Variation864.36
Mean Deviation124,958
Median17,540
Standard Deviation164,788
Sample Variance27.2B
Range578.2K
R-Value0.01
Mean Square Error29.2B
R-Squared0.0001
Significance0.97
Slope390.84
Total Sum of Squares380.2B

Lixte Change In Working Capital History

202421.6 K
202320.6 K
2022154.8 K
2021-13.4 K
2020-117.9 K
201917.5 K
2018-163.5 K

About Lixte Biotechnology Financial Statements

Lixte Biotechnology investors use historical fundamental indicators, such as Lixte Biotechnology's Change In Working Capital, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lixte Biotechnology. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Change In Working Capital20.6 K21.6 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Lixte Stock Analysis

When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.